

**FIRST-HALF 2007 RESULTS**
**CEGEDIM SUCCESSFULLY MANAGING ITS EXTERNAL GROWTH**

**Paris, 26 October 2007** - CEGEDIM, the European leader in CRM solutions and marketing studies for the pharmaceutical industry, generated an operational margin at 13%, in line with the first-half 2006 operational margin.

<i>In thousands of euros</i>	<b>30/06/2007 Net</b>	<b>30/06/2006 Net</b>	<b>Var %</b>
<b>Turnover</b>	<b>323,416</b>	<b>257,118</b>	<b>26%</b>
<b>Ordinary operating profit</b>	<b>42,450</b>	<b>33,421</b>	<b>27%</b>
Ordinary operating margin	13.1%	13.0%	
Net cost of financial liabilities	-14,772	-2,280	548%
Tax charge	-9,545	-10,137	-6%
Share of profit/loss from affiliated companies	-175	-17	929%
After-tax profit/loss from businesses held for sale	-131	-1,801	-93%
<b>Net consolidated profit</b>	<b>17,827</b>	<b>19,186</b>	<b>-7%</b>
Group share	17,755	19,105	-7%
Minority interests	72	81	-11%
Earning per share (in euros)	1.9	2.1	

<i>In thousands of euros</i>	<b>Turnover 30/06/07</b>	<b>EBIT 30/06/07</b>	<b>EBIT/TO 30/06/07</b>	<b>Turnover 30/06/06</b>	<b>EBIT 30/06/06</b>	<b>EBIT/TO 30/06/06</b>
CRM and strategic data	170,847	26,515	15.5%	119,717	20,056	16.8%
Healthcare professionals	71,675	9,890	13.8%	64,130	7,569	11.8%
Healthcare insurance services	40,587	2,305	5.7%	39,409	3,905	9.9%
Healthcare and strategic data	283,109	38,710	13.7%	223,256	31,530	14.1%
Technology and services	40,307	3,740	9.3%	33,862	1,891	5.6%
<b>Total Cegedim</b>	<b>323,416</b>	<b>42,450</b>	<b>13.1%</b>	<b>257,118</b>	<b>33,421</b>	<b>13.0%</b>

The Dendrite acquisition was the highlight of the first half of 2007. Dendrite contributed €45 million in consolidated revenues from 9 May 2007. In accordance with IFRS, the activities held for sale to Tessi are presented separately in the consolidated financial statements. Impact on sales is around €10 million. Excluding the Tessi impact, consolidated sales came to €333 million.

The “**CRM and strategic data**” sector, whose businesses cater to pharmaceutical companies, posted a strong operating margin close to 16%. French businesses confirm their maturity, while margins were bolstered by substantial international development.

The Group also generated substantial growth in H1 sales and operating margins in the “**Healthcare professionals**” businesses. The two-point increase in operating margin compared with H1 2006 was mainly fuelled by a sharp drop in the operating costs of Cegedim’s French medical software activities, which have generated losses for years but are on the road to becoming profitable.

“**Insurance services**” sector sales rose a steady 3% year on year. Operating margin for the first half of 2007 was 5.7%, dipping temporarily due to the launch of a promising new business: I-santé.

The “**Technology and services**” division’s operating margin rose substantially, particularly due to the fine performance of Cegelease.

Together, these factors produced an operating profit of €42 million.

The net profit of businesses held for sale to Tessi represented a loss to the company of €131,000, giving Cegedim Group a consolidated net profit of €17.8 million.

## **2007 outlook**

Cegedim Group is still confirming its full-year sales forecast, expecting overall growth of around 7% for the year (Dendrite’s impacts not included).

Ownership of activities sold was effectively transferred to Tessi on 2 July 2007.

## **About CEGEDIM:**

CEGEDIM has been developing exclusive databases and high value added software solutions since 1969.

Established as the world’s leading CRM provider for the life sciences industry with its Cegedim Dendrite business unit, CEGEDIM provides the world’s largest pharmaceutical companies with vital support for successful Customer Relationship Management (CRM). Its Cegedim Strategic Data and Cegedim Customer Information business units are also dedicated to pharmaceutical companies and help them improve sales & marketing effectiveness thanks to the Group’s strategic databases focused on the world drug market.

This expertise falls into the “Healthcare and strategic data” division of the CEGEDIM Group, which comprises the services specifically designed for pharmaceutical companies cited above and specific solutions dedicated to healthcare professionals (notably physicians and pharmacists in Europe) and health insurance providers.

The “Technologies and services” division capitalizes on the Group’s technical skills in order to provide specific solutions to clients of various sectors, essentially in France.

Cegedim generated turnover of €541 million in 2006. Including Dendrite, the combined Group’s pro forma 2006 revenue would amount to €877 million for a workforce of 7,500 and operations in more than 80 countries. To learn more, please see our website: [www.cegedim.com](http://www.cegedim.com)

Listed on Eurolist by Euronext Paris - Compartment B ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

### Media inquiries

#### **CEGEDIM**

Aude Balleydier  
Media Relations

Tél. : +33 1 49 09 68 81

[aude.balleydier@cegedim.fr](mailto:aude.balleydier@cegedim.fr)

#### **VP COMMUNICATION**

Coralie Voigt  
Press Officer

Tél. : +33 1 40 22 04 01

[cvoigt@vp-communication.com](mailto:cvoigt@vp-communication.com)

### Investor relations

#### **CEGEDIM**

Sandrine Debroise  
Chief Financial Officer

Antoine Alazard  
Special Advisor Financial Department

Annelise Falandry  
In charge of financial communication

Tél. : +33 1 49 09 22 00

[investor.relations@cegedim.fr](mailto:investor.relations@cegedim.fr)